The neuropsychopharmacology of cannabis: a review of human imaging studies

Michael A P Bloomfield, Chandni Hindocha, Sebastian F Green, Matthew B Wall, Rachel Lees, Katherine Petrilli, Harry Costello, M Olabisi Ogunbiyi, Matthijs G Bossong, Tom P Freeman

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The laws governing cannabis are evolving worldwide and associated with changing patterns of use. The main psychoactive drug in cannabis is Δ9-tetrahydrocannabinol (THC), a partial agonist at the endocannabinoid CB1 receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of cannabis, may offset some of these acute effects. Heavy repeated cannabis use, particularly during adolescence, has been associated with adverse effects on these systems, which increase the risk of mental illnesses including addiction and psychosis. Here, we provide a comprehensive state of the art review on the acute and chronic neuropsychopharmacology of cannabis by synthesizing the available neuroimaging research in humans. We describe the effects of drug exposure during development, implications for understanding psychosis and cannabis use disorder, and methodological considerations. Greater understanding of the precise mechanisms underlying the effects of cannabis may also give rise to new treatment targets.

Original languageEnglish
JournalPharmacology and Therapeutics
Early online date19 Oct 2018
DOIs
Publication statusE-pub ahead of print - 19 Oct 2018

Keywords

  • Addiction
  • Cannabis
  • Cognition
  • Development
  • Neuroimaging
  • Psychosis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The neuropsychopharmacology of cannabis: a review of human imaging studies. / Bloomfield, Michael A P; Hindocha, Chandni; Green, Sebastian F; Wall, Matthew B; Lees, Rachel; Petrilli, Katherine; Costello, Harry; Olabisi Ogunbiyi, M; Bossong, Matthijs G; Freeman, Tom P.

In: Pharmacology and Therapeutics, 19.10.2018.

Research output: Contribution to journalReview article

Bloomfield, MAP, Hindocha, C, Green, SF, Wall, MB, Lees, R, Petrilli, K, Costello, H, Olabisi Ogunbiyi, M, Bossong, MG & Freeman, TP 2018, 'The neuropsychopharmacology of cannabis: a review of human imaging studies', Pharmacology and Therapeutics. https://doi.org/10.1016/j.pharmthera.2018.10.006
Bloomfield, Michael A P ; Hindocha, Chandni ; Green, Sebastian F ; Wall, Matthew B ; Lees, Rachel ; Petrilli, Katherine ; Costello, Harry ; Olabisi Ogunbiyi, M ; Bossong, Matthijs G ; Freeman, Tom P. / The neuropsychopharmacology of cannabis: a review of human imaging studies. In: Pharmacology and Therapeutics. 2018.
@article{000b9d2b21f240c49962f3642ca13aa7,
title = "The neuropsychopharmacology of cannabis: a review of human imaging studies",
abstract = "The laws governing cannabis are evolving worldwide and associated with changing patterns of use. The main psychoactive drug in cannabis is Δ9-tetrahydrocannabinol (THC), a partial agonist at the endocannabinoid CB1 receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of cannabis, may offset some of these acute effects. Heavy repeated cannabis use, particularly during adolescence, has been associated with adverse effects on these systems, which increase the risk of mental illnesses including addiction and psychosis. Here, we provide a comprehensive state of the art review on the acute and chronic neuropsychopharmacology of cannabis by synthesizing the available neuroimaging research in humans. We describe the effects of drug exposure during development, implications for understanding psychosis and cannabis use disorder, and methodological considerations. Greater understanding of the precise mechanisms underlying the effects of cannabis may also give rise to new treatment targets.",
keywords = "Addiction, Cannabis, Cognition, Development, Neuroimaging, Psychosis",
author = "Bloomfield, {Michael A P} and Chandni Hindocha and Green, {Sebastian F} and Wall, {Matthew B} and Rachel Lees and Katherine Petrilli and Harry Costello and {Olabisi Ogunbiyi}, M and Bossong, {Matthijs G} and Freeman, {Tom P}",
note = "Copyright {\circledC} 2018 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2018",
month = "10",
day = "19",
doi = "10.1016/j.pharmthera.2018.10.006",
language = "English",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier",

}

TY - JOUR

T1 - The neuropsychopharmacology of cannabis: a review of human imaging studies

AU - Bloomfield, Michael A P

AU - Hindocha, Chandni

AU - Green, Sebastian F

AU - Wall, Matthew B

AU - Lees, Rachel

AU - Petrilli, Katherine

AU - Costello, Harry

AU - Olabisi Ogunbiyi, M

AU - Bossong, Matthijs G

AU - Freeman, Tom P

N1 - Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2018/10/19

Y1 - 2018/10/19

N2 - The laws governing cannabis are evolving worldwide and associated with changing patterns of use. The main psychoactive drug in cannabis is Δ9-tetrahydrocannabinol (THC), a partial agonist at the endocannabinoid CB1 receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of cannabis, may offset some of these acute effects. Heavy repeated cannabis use, particularly during adolescence, has been associated with adverse effects on these systems, which increase the risk of mental illnesses including addiction and psychosis. Here, we provide a comprehensive state of the art review on the acute and chronic neuropsychopharmacology of cannabis by synthesizing the available neuroimaging research in humans. We describe the effects of drug exposure during development, implications for understanding psychosis and cannabis use disorder, and methodological considerations. Greater understanding of the precise mechanisms underlying the effects of cannabis may also give rise to new treatment targets.

AB - The laws governing cannabis are evolving worldwide and associated with changing patterns of use. The main psychoactive drug in cannabis is Δ9-tetrahydrocannabinol (THC), a partial agonist at the endocannabinoid CB1 receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of cannabis, may offset some of these acute effects. Heavy repeated cannabis use, particularly during adolescence, has been associated with adverse effects on these systems, which increase the risk of mental illnesses including addiction and psychosis. Here, we provide a comprehensive state of the art review on the acute and chronic neuropsychopharmacology of cannabis by synthesizing the available neuroimaging research in humans. We describe the effects of drug exposure during development, implications for understanding psychosis and cannabis use disorder, and methodological considerations. Greater understanding of the precise mechanisms underlying the effects of cannabis may also give rise to new treatment targets.

KW - Addiction

KW - Cannabis

KW - Cognition

KW - Development

KW - Neuroimaging

KW - Psychosis

UR - http://www.scopus.com/inward/record.url?scp=85056409389&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2018.10.006

DO - 10.1016/j.pharmthera.2018.10.006

M3 - Review article

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -